Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FAZ 053

Next Previous
Drug Profile

FAZ 053

Alternative Names: FAZ-053; LAE005

Latest Information Update: 22 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis Pharmaceuticals
  • Developer Laekna Therapeutics; Novartis Pharmaceuticals
  • Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 13 Jan 2025 Novartis Pharmaceuticals terminates a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in US, Canada, France, Israel, Italy, Japan, Singapore, Spain and Taiwan (NCT02936102)
  • 05 Apr 2024 Efficacy and adverse events data from a phase I/II trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 28 Dec 2022 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease) in Canada (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top